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Abstract
Background: Growth-based drug susceptibility testing (DST) is the reference standard for diagnosing drug-resistant
tuberculosis (TB), but standard time to result (TTR) is typically ≥ 3 weeks. Rapid tests can reduce that TTR to days or
hours, but accuracy may be lowered.
In addition to the TTR and test accuracy, the cost of a diagnostic test may affect whether it is adopted in clinical
settings. We examine the cost-effectiveness of rapid diagnostics for extremely drug-resistant TB (XDR-TB) in three
different high-prevalence settings.
Methods: 1128 patients with confirmed TB were enrolled at clinics in Mumbai, India; Chisinau, Moldova; and Port
Elizabeth, South Africa. Patient sputum samples underwent DST for first and second line TB drugs using 2 growth-based
(MGIT, MODS) and 2 molecular (Pyrosequencing [PSQ], line-probe assays [LPA]) assays. TTR was the primary measure of
effectiveness. Sensitivity and specificity were also evaluated. The cost to perform each test at each site was recorded and
included test-specific materials, personnel, and equipment costs. Incremental cost-effectiveness ratios were calculated in
terms of $/day saved. Sensitivity analyses examine the impact of batch size, equipment, and personnel costs.
Results: Our prior results indicated that the LPA and PSQ returned results in a little over 1 day. Mean cost per sample
without equipment or overhead was $23, $28, $33, and $41 for the MODS, MGIT, PSQ, and LPA, respectively. For
diagnosing XDR-TB, MODS was the most accurate, followed by PSQ, and LPA. MODS was quicker and less costly than
MGIT. PSQ and LPA were considerably faster but cost more than MODS. Batch size and personnel costs were the main
drivers of cost variation.
Conclusions: Multiple factors must be weighed when selecting a test for diagnosis of XDR-TB. Rapid tests can greatly
improve the time required to diagnose drug-resistant TB, potentially improving treatment success, and preventing the
spread of XDR-TB. Faster time to result must be weighed against the potential for reduced accuracy, and increased costs.
Trial registration: ClinicalTrials.gov Identifier: NCT02170441.
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Background
Tuberculosis (TB) remains a leading cause of mortal-
ity globally [1]. Drug-resistant strains of TB (DR-TB)
have emerged, mostly due to inadequate or incom-
plete treatment [2]. To diagnose and then appropri-
ately treat DR-TB, it is important to conduct drug
susceptibility testing (DST), especially in regions known
to have high levels of DR-TB [2, 3]. Effectively diagnosing
and treating drug-resistant TB is key to reducing transmis-
sion [4], improving treatment outcomes and lowering
mortality.
In response to the long time to result (TTR) inher-
ent in conventional reference methods for diagnosing
DR-TB, novel, rapid DST methods are becoming
available [5–7]. In addition, an international consortium
was established to evaluate microbiological and molecular
assays for quickly and efficiently detecting DR-TB [8, 9].
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In addition to TTR, there are a number of other
important characteristics of DR-TB assays that should be
considered, including the accuracy and the cost of new
tests [10, 11]. A test that is rapid but not accurate may be
of questionable value, and an accurate and rapid test may
be inaccessible if it is costly [12]. Thus it is important to
consider all three of these characteristics (test accuracy,
time to result, and cost of the test) when evaluating novel
DR-TB diagnostics [13]. The objective of our study was to
compare the cost-effectiveness of three currently available,
rapid diagnostic tests to MGIT960 DST, a WHO recom-
mended reference standard [1, 14, 15]. The data will allow
experts to gauge whether shorter time to result or in-
creased accuracy is worth additional costs for certain new
diagnostic tests.
Methods
Study design
The parent study design and methods have been previously
described elsewhere [9]. Briefly, the goal of the overall
study was to compare the TTR and the sensitivity/specifi-
city of three rapid tests for diagnosis of extremely drug
resistant tuberculosis (XDR-TB) to MGIT DST. XDR-TB is
defined as resistance to both isoniazid and rifampicin, as
well as any one of the fluoroquinolones, and any
one of the injectable anti-TB drugs [1]. The diagnos-
tic tests were run in parallel on study participants at
three large TB clinics located in areas of elevated
XDR-TB prevalence. Participants suspected of having
XDR-TB were enrolled (see Additional file 1: Table
S1 for inclusion/exclusion criteria) [9]. Biological
specimens and interview data were collected at baseline
and 52-week follow-up visits. In addition, medical record
reviews were conducted at baseline, 30 days post-
enrollment and 52 weeks post-enrollment. Enrollment oc-
curred between June 2012 and June 2013. Participants
were not compensated for participation, but travel costs
were reimbursed when patients traveled an hour or more
for research-related visits.
Study sites
The three study sites were located in Mumbai, India;
Port Elizabeth, South Africa; and Chisinau, Moldova.
India
The P.D. Hinduja National Hospital (PD-HNH) and
Medical Research Centre (MRC), is a tertiary care center
in central Mumbai, India. The Pulmonary Department
at the PD-HNH is the busiest in Mumbai and is the
referral center for MDR and XDR-TB cases from the
Mumbai and the state of Maharashtra. In a previous
study of the patient population at this clinic, 80% of
samples obtained were found to be resistant to one or
more standard TB medications, while 51% were resistant
to more than one drug [16].
Moldova
The Phthisiopneumology Institute (PPI) in Chisinau,
Moldova is the central unit of the National TB Control
Programme. It is a medical consultation, scientific
research, and training center that leads all TB patient
services across Moldova. Moldova has a high prevalence
of drug resistant TB, with 24% of new and 62% of previ-
ously treated TB patients having MDR-TB [17].
South Africa
According to the WHO, South Africa has a high number
of incident TB cases and a high prevalence of drug-
resistant TB [9]. At the Port Elizabeth site, patients were
enrolled at six primary health care facilities and one
regional hospital. The decentralized enrollment resulted
in a lower prevalence of drug resistance at this site [1].
Experience and training of laboratory personnel Each
of the study sites described above had existing clinical
laboratories that had been in operation for many years
and adhered to international safety standards. The study
required each site to identify a laboratory technician
with at least one year experience conducting TB testing.
Each site had ongoing experience conducting drug-
resistance testing for TB using the MGIT and line-probe
assay. For these tests, each site was sent a set of samples
to test and site results were compared to previously
established findings at the coordinating center (UCSD).
The lab technician from each site also jointly attended a
week-long training for the MODS at the Universidad
Peruana Cayetano Heredia in Lima, Peru and a week-
long training on Pyrosequencing with Dr. Grace Lin at
the California Department of Public Health, Richmond,
California. Training consisted of lecture, lab instruction,
and hands on training to establish standardized testing
procedures across sites.
Inclusion/exclusion criteria
To be eligible for the study, participants had to a) be at
least 5 years of age; b) have provided informed consent or
had ability and willingness of subject or legal guardian/
representative to provide informed consent; c) known to
be AFB sputum smear-positive (defined as 1+ or greater
within prior 14 days), positive on GeneXpert, or present
clinically with high suspicion of active TB and:
– Had previously received > 1 month of treatment for
a prior TB episode or
– Were failing TB treatment with positive sputum
smear or culture after ≥3 months of a standard TB
treatment or
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– Had had close contact with a known drug-resistant
TB case or
– Were newly diagnosed with MDR-TB within the last
30 days or
– Were previously diagnosed with MDR-TB and failed
TB treatment with positive sputum smear or culture
after ≥3 months of a standard MDR-TB treatment
regimen.
– Exclusion criteria were a) institutionalized; b) unable
to provide at least 7.5 ml sputum (1st and 2nd
samples combined) or c) had results from second
line DST performed within the last 3 months.
Study measures
Effectiveness
The TTR of each assay was the primary effectiveness
outcome. TTR was defined as “the number of days from
initiation of testing to recording of final results of all
seven drugs for each test”. The date was tracked and re-
ported at key steps during assay processing. The sensi-
tivity and specificity of each of the three novel tests
(MODS, LPA, PSQ) when compared to the reference
standard (MGIT) served as an additional measure of ef-
fectiveness. The presence or absence of an interpretable
result was also recorded.
Costs
Test-specific materials and personnel costs The local
costs of test-specific laboratory materials and personnel
costs were collected at each site using a survey for each
diagnostic test using local currency. To ensure accuracy
and uniformity of data collection across sites, staff were
trained via web- and tele-conferencing on how to
complete the surveys. Surveys were completed 3–6 months
after enrollment began to allow sites to develop profi-
ciency on any new tests. Costs were listed per batch, and
information was gathered on the mean batch size. Site
staff were instructed to exclude research-specific costs.
When processes were shared across tests, the full cost of
that process was counted for each test. Completed surveys
were reviewed by investigators at the coordinating site.
Missing data or inconsistencies were identified, and sites
were asked to clarify the data.
Test-specific equipment costs Although some equip-
ment was already owned by the study sites, we applied
the 2010 purchase price for all required equipment and
amortized these costs over a recommended useful life of
ten years to be consistent across sites [18].
A per sample cost for test-specific equipment was
calculated by dividing the total cost by the projected
number of samples over ten years using actual test vol-
ume. The cost of test-specific equipment per sample was
then calculated. Ranges based on volume from the other
study sites and a maximum volume was also estimated.
General lab equipment and overhead costs In addition
to test-specific materials and equipment, each site had
existing general laboratory equipment that was used for
the study. Examples are standard beakers, storage cabi-
nets, etc. In addition, there were overhead costs related
to building space, utilities, and ongoing maintenance.
However, it was not possible to accurately separate general
lab equipment and overhead costs used for the current
study from those used for non-study clinical services. In
addition, general equipment and overhead costs were cov-
ered through national government health systems at some
sites and were not available. Thus, overhead costs were
estimated at 69% of the personnel costs required to deliver
the intervention. The overhead cost estimate accounts for
facilities costs, indirect support personnel, and other
typical indirect costs associated with running a medical
clinic [19]. This figure is based on data showing that indir-
ect costs are another 69% above medical personnel costs
[20]. This method has been used in other cost-effectiveness
analyses [21, 22].
Cost analyses
All analyses were conducted from the health care
organization perspective. Patient costs were not tracked.
All local currency costs were converted to US Dollars
using the international currency exchange data reported
on XE.com in June 2013. [http://www.xe.com/currency-
converter/] Exchange rates were 1 Dollar = 58.82 Indian
Rupees, 12.20 Moldovan Leu, and 9.70 South African
Rand. Once converted to US Dollars, personnel costs for
India, were $1.52, $1.82, and $4.55/h for an assistant
laboratory technician, laboratory technician, and labora-
tory supervisor, respectively. For Moldova, personnel
costs were $1.50, $2.50, or $3.50/h for cleaning
personnel, a laboratory technician, and a laboratory
supervisor, respectively. For South Africa, all activities
were conducted by a laboratory technician at wages of
$10.30/h. The mean cost per sample for materials and
personnel were calculated separately and then combined in
an initial “operations-only” incremental cost-effectiveness
analysis. Next, test-specific equipment costs were added to
the analysis. A third analysis reflected the addition of over-
head costs. Incremental cost-effectiveness ratios (ICER)
were calculated for each analysis.
Sensitivity analyses
Sensitivity analyses were used to explore how the incre-
mental cost-effectiveness analysis results changed when
inputs were varied. Inputs that either varied across sites or
may vary considerably under other conditions included
batch size, hourly wage for laboratory personnel, and
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lifetime samples processed for test-specific equipment.
Thus, it is informative to study the impact of these variables
on the study results [23]. Sensitivity analyses were
conducted by entering the high and low value from the
range of values explained below into the Excel spreadsheets
used for calculations. Each cost component (materials,
personnel, test-specific equipment, and overhead) was then
recalculated and combined into total cost/sample. Each
1-way analysis examined the individual sensitivity of results
when batch, hourly wage, and equipment costs were varied
separately. Next, the high and low values for two of the
three variables were added together. Two-way sensitivity
analyses were run for paired variables of batch size/mean
hourly wage and batch size/mean equipment cost. The first
two-way pair is of interest because two study sites had both
low mean hourly wage and higher batch sizes. The second
two-way pair is of interest because high volume sites are
likely to maximize batch size and also have a reduced per
sample equipment cost while the opposite is true of sites
with low testing volumes. Finally, a three-way sensitivity
analysis was conducted, co-varying the range of values for
laboratory batch size, mean hourly wage, and mean equip-
ment cost. The sensitivity tornado chart was produced
using Microsoft Excel add-on software.
Batch sizes varied across the sites depending on patient
volumes at each site. Batches of PSQ were limited to a
maximum of 12 per batch. Batches of the MGIT test were
limited to eight samples per well. Each sample was tested
with all four tests, so batches remained in the range of
5–12 per batch so that one test was not lagging behind.
We varied batch sizes from the minimum to the maximum
reported in our study. We also varied personnel costs by
the ranges reported in our study.
As described above, hourly wages ranged from $1.50 per
hour to $10.30 per hour. However, personnel costs were
also affected by time spent on each task, and sites with
lower wages tended to use multiple levels of staffing.
Because the actual volume of tests performed with our
study equipment may have significantly underestimated
total potential volume per machine, we varied the volume
from the lowest seen at our study sites, to a maximum of
2000 DST tests per year. We estimated that the PSQ could
use its 96 wells to test 12 samples x seven drugs and one
control approximately every two days, providing DST on
about 2000 samples annually. While more than 2000 sam-
ples could be tested with the other diagnostic tools, we
used the 2000 tests maximum to standardize the compari-
son across tests.
Results
Operations cost by test
Demographic information for the sample have been pub-
lished previously [8], and clinical characteristics are
available as Additional file 1: Table S1. Operations costs
for each test at the three study sites are presented in
Table 1. Materials costs varied considerably between sites
for the various diagnostic tests. With the exception of the
MODS test, India reported higher expenses for consum-
able laboratory materials. Personnel effort also varied
across sites. For the MGIT culture and DST, Moldova
spent twice as many hours completing each batch. For all
tests, South Africa had the highest cost/sample, mostly be-
cause of higher wages as described above. However, South
Africa also reported testing the smallest number of sam-
ples per batch for most tests, which increased the per
sample cost.
Test-specific equipment costs
Equipment costs are presented in Table 2. It is noted if
equipment was used for more than one diagnostic test.
The MGIT and PSQ had large equipment costs because
they require expensive machinery while MODS had
minimal equipment costs.
Total cost per sample with overhead
Table 3 presents the total costs per sample for each diag-
nostic test. MODS was cheaper than the MGIT (culture +
and DST), with the difference driven by MGIT having a
larger equipment cost. The PSQ total costs were slightly
higher than MGIT, but considerably less than the LPA
tests. The LPA test required little equipment but was
more costly due to higher materials and personnel costs
associated with conducting both the MTBDRsl and
MTBDRplus assays for XDR-TB diagnosis.
Incremental cost-effectiveness
The direct cost subtotal (operations plus equipment
costs) was chosen for the final cost-effectiveness analysis
because it was more accurately measured than overhead
costs which were estimated. Table 4 presents the main
incremental cost effectiveness analysis and showed that
MODS had a lower cost and a shorter TTR than MGIT,
thus dominating that comparison. Ranking third in cost
per sample, the PSQ was compared to the previous best
choice; MODS. PSQ costs $25.46 more per sample than
MODS but was 13.2 days faster, producing an ICER of
$25.46/13.2 = $1.93/day saved. Finally, the combined
LPA tests were more costly than the previous best
choice (PSQ), but did not provide additional effective-
ness (time to result) for calculating an ICER.
Test accuracy
Sensitivity and specificity results for the three rapid tests
compared to MGIT DST from sputum for the diagnosis
of XDR-TB and MDR-TB are shown in Tables 5 and 6,
respectively. Sensitivity and specificity results for the
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three rapid tests compared to MGIT DST for individual
drugs have been previously published [24] but are also
available in Additional file 1: Table S2.
Sensitivity results
Analysis inputs (batch size, hourly wage, equipment cost)
were varied individually and in combination (Fig. 1).
When batch size was maximized using our study site data,
LPA became less expensive than PSQ and returns the low-
est ICER. In almost all scenarios, MODS remains the least
expensive test and is faster than MGIT (Table 5). When
hourly wage was varied between $2 and $10 per hour, the
ICERs changed very little, ranging from $1.88 to $1.81,
respectively. Equipment costs play a significant role in
PSQ and MGIT costs, and are affected by equipment life-
time volume. In a low volume site, equipment costs for
Table 1 Operations costs for XDR-TB diagnostic tests by study site (in US $ unless otherwise noted)a
MGIT (culture and DST) LPA (plus and sl) MODS PSQ
Moldova India South Africa Moldova India South Africa Moldova India South Africa Moldova India South Africa
Materials in $ 126 274 187 372 525 338 114 42 161 296 353 325
Personnel (in Hours) 8.7 5.7 4.0 12.2 17.0 16.0 6.0 5.5 5.5 11.3 8.5 12.0
Personnel cost $/batch 23 11 41 33 47 165 18 20 57 30 28 124
Total cost$/ batch 149 285 228 405 572 503 132 62 218 326 381 449
# samples/batch 8 8 5 12 12 5 4 6 5 11 12 9
Cost/sample in $ 18.56 35.65 45.61 33.73 47.69 100.50 32.88 10.35 43.56 29.64 31.76 49.90
aActual costs were tracked once sites had developed test proficiency (performing a test for at least 3 months)
DST Drug susceptibility testing, LPA Line-probe assay, MGIT Mycobacteria Growth Indicator Tube, MODS Microscopic-observation drug-susceptibility assay, PSQ Py-
rosequencing, US United States, XDR-TB Extremely drug-resistant tuberculosis
Table 2 Test-specific equipment costs (US$)
GCDD Equipment use 1 use 2 MGIT LPAs MODS PSQ
MGIT machine BD MGIT 47,500
Inverted microscope MODS 2888
Pyromark 96 ID PSQ 81,086
Pyro Vacuum Workstation PSQ 5053
Pyro Assay Design software PSQ 943
Pyro IdentiFire software PSQ 1734
PCR Workstation LPA PSQ 3368 3367
Ultrasonic waterbath LPA PSQ 2790 2790
Plate shaker 230 V PSQ 734
Block Heater Digital-230 V LPA PSQ 1323 1323
Water bath - heat LPA PSQ 593 593
Uninterruptible power supply PSQ 544
Twincubator (Hain) LPA 2441
Ultrapure water filtration PSQ 1167
Mini-Plate Spinner Centrifuge PSQ 1220
Mini Centrifuge LPA PSQ 771 771
Mini Vortex LPA PSQ 722 722
Totals $47,500 $12,008 $2888 $102,048
Mean samples/batch (range) 7.0 (5–8) 9.67 (5–12) 5.0 (4–6) 10.67 (9–12)
Samples in equipment lifetime (520 weeks) 3640
(2600–4160)
5028
(2600–6240)
2600
(2080–3120)
5547
(4680–6240)
Mean cost/sample
(range by batch size)
$13.05
(11.42–18.27)
$2.39
(1.86–4.47)
$1.11
(0.93–1.39)
$18.40 ($16.35–21.81)
Minimum cost/sample
(2000 tests/year)
$2.38 $0.60 $0.14 $5.10
LPA Line-probe assay, MGIT Mycobacteria Growth Indicator Tube, MODS Microscopic-observation drug-susceptibility assay, PSQ Pyrosequencing, US United States
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PSQ increase the ICER to $2.19 per day saved. However, if
a site conducted 2000 tests per year over the life of the
machines, the ICER for the PSQ compared to MODS is
reduced to $0.99.
Figure 1 Sensitivity Analysis Graph of the incremental
cost/day saved in diagnosis time by laboratory batch size,
mean hourly wage, and mean equipment cost (as a result
of testing volume). Solid line reflects decreases, and
striped line increases, in the incremental cost-effectiveness
ratios as analytic components along the y-axis are varied
across the range of values observed in the study.
In two-way sensitivity analyses, varying batch size and
equipment from high to low volume provides ICERs of
$1.14 to $2.19 for PSQ versus MODS. Varying hourly
wage and batch size together produces larger swings in
the predicted ICERs. Smaller batch sizes and higher
wages ($10) result in an ICER of $2.61 per day saved for
PSQ versus MODS. With larger batch sizes and lower
wages, the LPA tests again becomes less expensive than
PSQ, and provides an ICER of $0.70 per day saved (LPA
vs. MODS). Finally, in three-way analysis, small batch
size, high wages, and low volume equipment use result
in the highest cost per day saved ($2.85). while large
batches, low wages, and a high sample volume provide
the lowest ICER of $0.22, with MGIT becoming less
expensive than MODS.
Discussion
Using actual study data, MODS is the least expensive
test per sample, and is ten days faster than MGIT DST,
with good sensitivity/specificity for MDR-TB, but lower
accuracy for XDR-TB. The LPA tests (MTBDRsl and
MTBDRplus) and the PSQ provide results in one day,
shaving 13 more days off the TTR, but with increased
costs. Like MODS, these tests had high sensitivity/speci-
ficity for MDR-TB diagnosis, but accuracy drops for
XDR-TB.
Despite significantly higher equipment costs per sam-
ple, PSQ costs less than LPA overall, especially when
volume if high, making it a leading choice for a rapid
diagnostic test that can provide a result within one day.
Once the PSQ equipment is purchased, the operating
costs for this test were about $37/sample in our study,
only a few dollars more than MGIT DST with culture
and about $9 more per sample than MODS. For clinical
sites than cannot afford the PSQ machine, the MODS
assay may be a viable and scalable option for detecting
XDR-TB in clinical samples. However, MODS may re-
quire more intensive biohazard control measures than
the molecular assays which do not require growth of TB
cultures. However, the difference may be of little impact
because most sites would already have safety measures
for culture-based testing in place.
When accounting for tests that had to be re-run
because of indeterminate or failed tests, we incorporated
the proportion of interpretable results for each test by div-
iding the cost per sample for each test by this ratio, pro-
viding a cost per valid result. The PSQ was able to provide
a result 84% of the time within 1.1 days, while both the
MODS and LPA delivered interpretable results approxi-
mately 80% of the time. (Additional file 1: Table S3) Thus,
while the rate of indeterminate tests varied by the drug
being tested, the PSQ provided significantly more inter-
pretable results overall. This slightly improved the cost
Table 3 Mean costs /sample adding various components (US$)
Diagnostic
Test
Mean Operating
Costs
Test-Specific
Equipment
Costs
Direct Cost
Subtotal
General Equipment
and Overhead
per sample
Total
Cost/sample
MGIT $33.27 $13.05 $46.32 $4.00 $50.32
LPAs $60.64 $2.39 $63.03 $9.13 $72.16
MODS $28.93 $1.11 $30.04 $4.35 $34.39
PSQ $37.10 $18.40 $55.50 $3.90 $59.40
LPA Line-probe assay, MGIT Mycobacteria Growth Indicator Tube, MODS Microscopic-observation drug-susceptibility assay, PSQ Pyrosequencing, US United States
Table 4 Incremental cost-effectiveness of diagnostic tests for XDR-TB
Diagnostic
Test
Mean cost
/sample ($)
Effectiveness (days to XDR
diagnosis)
Incremental cost/sample
($US)
Incremental
effectiveness
Incremental cost effectiveness
($/day saved)
MODS $30.04 14.3 days – – –
MGIT $46.32 24.7 days $16.28 dominated dominated
PSQ $55.50 1.1 days $25.46 13.2 $1.93/day saved
LPA plus
and sl
$63.03 1.1 days $7.53 dominated dominated
LPA Line-probe assay, MDR-TB Multi-Drug Resistant Tuberculosis, MGIT Mycobacteria Growth Indicator Tube, MODS Microscopic-observation drug-susceptibility
assay, PSQ Pyrosequencing, US United States, XDR-TB Extremely-Drug Resistant Tuberculosis
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per interpretable result for the PSQ relative to the other
two tests, potentially enhancing it as a cost-effective
choice in some contexts.
To our knowledge, no previous studies have examined
the costs of different rapid diagnostic tests for both
MDR-TB and XDR-TB, making it hard to interpret our
ICER results. However, our cost/sample for the tests are
quite similar to those found in other studies. For
example, our MGIT DST costs are quite similar to previ-
ous figures of about $37 (operations only) [25] and $56
(overhead) [14] found in previous cost studies. The $36
per sample (half of $72) we found was still higher than
those found for either LPA test in previous studies
($23–26) [26, 27], primarily because of high costs at our
South Africa site (lower volume and batch size with high
wages). When omitting South Africa site data, costs
become very close to previous results. While previous
studies conclude that MODS is a low-cost method for
detecting active TB, almost all use only materials costs
and do not report a detailed cost analysis [28, 29]. One
study estimated the overall costs of using MODS for 1st
line drugs and reported costs in Peru around $5 per
sample [30]. Our study is the only known study to report
a comprehensive cost analysis of MODS for obtaining
an XDR diagnosis. Thus, good comparisons were not
available for the cost of MODS in our study.
Costs varied considerably across our three study sites.
Materials costs were subject to fluctuation because of
availability, delivery costs, and currency conversion rates.
Personnel costs were about four to five times higher in
Port Elizabeth, South Africa than in Moldova or India,
partially because they employed a single higher level
laboratory technician for the study while the other sites
employed multiple levels of staff, including lab assistants.
It is notable that the higher paid personnel in South Af-
rica required less time to accomplish most diagnostic
tests. Batch sizes also tended to be the smallest in South
Africa, due to a lower volume of participants recruited
per week, which may be unique to the research environ-
ment. The higher costs in South Africa did not result in
better test performance on the PSQ [31].
In sensitivity analyses, varying these basic values
obtained from our sites, our results were insensitive to
most of the assumptions tested, providing a similar
result in most cases. A few exceptions worth noting are
that, when batch size was maximized by itself or in
addition to low hourly wages the LPA became less
expensive than PSQ, independent of indeterminate/failed
test rates. However, when equipment costs were also
minimized through high volume use in addition to max
batch size and low hourly wages, the MGIT is the least
expensive test and PSQ becomes less expensive than
LPA once again. This scenario is not unrealistic for clin-
ical sites in many countries where DR-TB is prevalent
and wages are low.
Our study was limited to using TTR and accuracy of
the three rapid diagnostic tests as a measure of effective-
ness because to properly compare the tests, it was im-
portant to conduct all four tests with every study
sample. This means treatment decisions and treatment
outcomes could not be assigned to a given test. In
addition, the sites varied in their familiarity with some
tests and thus would vary on which test they used to
make treatment decisions. Therefore, we were unable to
Table 5 Agreement between three rapid tests and MGIT for detection of XDR-TB
Sensitivity (95%
CI)
Specificity (95%
CI)
PPV (95% CI) NPV (95% CI) LR+ (95% CI) LR- (95% CI) % Agreement (95%
CI)
XDR LPA (n = 656) 0.49 (0.36, 0.61) 1.00 (0.99, 1.00) 1.00 (0.87,
1.00)
0.94 (0.92,
0.96)
– 0.51 (0.41,
0.65)
0.95 (0.93, 0.96)
MODS (n =
674)
0.83 (0.72, 0.91) 1.00 (0.99, 1.00) 0.97 (0.88,
0.99)
0.98 (0.97,
0.99)
251 (63,
1003)
0.17 (0.10,
0.28)
0.98 (0.96, 0.99)
PSQ (n = 538) 0.69 (0.56, 0.79) 1.00 (0.98, 1.00) 0.96 (0.85,
0.99)
0.96 (0.93,
0.97)
162 (40, 651) 0.32 (0.22,
0.45)
0.96 (0.94, 0.97)
CI Confidence Interval, LPA Line-probe assay, LR- Negative Likelihood Ratio, LR+ Positive Likelihood Ratio, MGIT Mycobacteria Growth Indicator Tube, MODS
Microscopic-observation drug-susceptibility assay, NPV Negative Predictive Value, PPV Positive Predictive Value, PSQ Pyrosequencing, XDR-TB Extremely-Drug
Resistant Tuberculosis
Table 6 Agreement between three rapid tests and MGIT for detection of MDR-TB
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
LR+
(95% CI)
LR-
(95% CI)
% Agreement
(95% CI)
MDR LPA (n = 656) 0.99 (0.97, 0.99) 1.00 (0.97, 1.00) 1.00 (0.99, 1.00) 0.97 (0.94, 0.99) 217 (31, 1534) 0.01 (0.01, 0.03) 0.99 (0.98, 1.00)
MODS (n = 674) 1.00 (0.98, 1.00) 1.00 (0.97, 1.00) 1.00 (0.99, 1.00) 0.99 (0.96, 1.00) 216 (31, 1527) 0.00 (0.00, 0.02) 1.00 (0.99, 1.00)
PSQ (n = 538) 0.99 (0.97, 0.99) 0.99 (0.95, 1.00) 1.00 (0.98, 1.00) 0.96 (0.91, 0.98) 135 (19, 951) 0.02 (0.01, 0.03) 0.99 (0.97, 0.99)
CI Confidence Interval, LPA Line-probe assay, LR- Negative Likelihood Ratio, LR+ Positive Likelihood Ratio, MDR-TB Multi-Drug Resistant Tuberculosis, MGIT Myco-
bacteria Growth Indicator Tube, MODS Microscopic-observation drug-susceptibility assay, NPV Negative Predictive Value, PPV Positive Predictive Value,
PSQ Pyrosequencing
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study the down-stream impact of shorter TTR and/or
reductions in sensitivity or specificity on treatment and
health outcomes of study patients while comparing the
tests. However, a shorter TTR is of obvious importance.
In all three of the countries studied, many patient travel
significant distances to receive health care from remote
locations. With many people traveling 6–12 h or more
to receive care, keeping them at the facility or nearby for
1–2 days while DR-TB presence or absence is confirmed
may have a major impact on both the spread of the
infection as well as on the length and quality of life of
the patient that presented.
Other limitations
As part of our study, sites were not eligible for discounts
on equipment or materials for conducting certain tests.
These discounts can be sizable for developing countries
[14], and should be considered when making decisions
on diagnostic tools for detecting DR-TB.
The current study did not quantify and report the
amount of time it took to train laboratory personnel on
each of the four tests because not all tests were new.
Thus sites differed in their familiarity with the tests mak-
ing it difficult to provide an accurate and comparable
summary of training time and experience.
While our inclusion of three different sites is a
strength, sites varied considerably in the costs they paid
for materials, in their personnel structure, and in wages.
Thus, using the mean cost/sample across the three sites
may not always provide the best comparison when gen-
eralizing the results to other clinical settings. Costs by
site are presented, allowing readers to make the most
appropriate comparisons for their needs. However, even
site specific costs are affected by currency exchange
rates and changing availability of materials. The site in
South Africa was a high volume site but could only
conduct all four research tests on a more limited set of
samples. Thus, test costs were likely inflated because of
the limited volume of samples studied.
Finally, the accuracy of the rapid tests is based on the
assumption that MGIT DST is 100% accurate, which is
likely not the case. It is possible that one or more of the
rapid tests may be more accurate, which would change
the results and conclusions. Further research in this area
is needed to determine this.
Conclusion
In conclusion, our analysis presents the costs associated
with three rapid diagnostic tests with good accuracy for
the detection of XDR-TB. MODS typically provided a
quicker time to result and was less expensive than
MGIT DST. The PSQ and LPA tests both provided
results much more rapidly and had similar sensitivity
and specificity. However, testing volume, the upfront
cost of expensive equipment, and potential discounts for
developing countries should be considered when decid-
ing which diagnostic test to use.
Our study demonstrates that there are many different
factors that affect the actual cost of conducting rapid
tests for XDR-TB in clinical practice. Equipment costs,
laboratory materials costs, testing volume, and monetary
exchange rates are all very important, as are levels of
existing laboratory infrastructure. The estimated costs to
conduct each test in our study were very similar to those
found in previous studies, confirming the relevance of
our results. The results allow clinical sites and organizations
Fig. 1 Sensitivity Analyses varying main components of the ICER. a LPA ICER ratio relative to the optimal choice of MODS. b PSQ ICER ratio
relative to the optimal choice of MODS. c MODS ICER ratio relative to the optimal choice of MGIT
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to roughly estimate their own costs based on characteristics
of the three clinical sites in our study. The rapid diagnostic
tests studied offer TB clinics and health organizations a var-
iety of options for improving their time to result for XDR
diagnosis, depending on their economic options. Our study
forms a solid comparator for future cost-effectiveness stud-
ies of XDR-TB diagnostic technologies.
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Patients. Table S2 Agreement between three rapid tests and MGIT for
detection of resistance for isoniazid (INH), rifampin (RIF), amikacin (AMK),
capreomycin (CAP), kanamycin (KAN), moxifloxacin (MOX), and ofloxacin
(OFX). Table S3 Proportion of total assay runs that produced
interpretable results from three diagnostic platforms (LPA, PSQ and
MODS) with the ability to detect resistance to isoniazid (INH), rifampin
(RIF), amikacin (AMK), capreomycin (CAP), kanamycin (KAN), moxifloxacin
(MOX), and ofloxacin (OFX). (DOCX 35 kb)
Abbreviations
DR-TB: Drug-resistant tuberculosis; DST: Drug susceptibility testing;
GCDD: Global Consortium for Drug-resistant TB Diagnostics;
ICER: Incremental cost-effectiveness ratios; LPA: Line-probe assay; MDR-
TB: Multi drug-resistant TB; MGIT: Mycobacteria Growth Indicator Tube;
MODS: Microscopic-observation drug-susceptibility assay;
PSQ: Pyrosequencing; TB: Tuberculosis (TB); TTR: Time to result; XDR-
TB: Extremely drug-resistant TB
Acknowledgements
Not applicable.
Funding
The Global Consortium for Drug-resistant TB Diagnostics (GCDD; http://
gcdd.ucsd.edu) was funded by the National Institute of Allergy and Infectious
Diseases (NIAID) grant U01-AI082229.
Availability of data and materials
In the conduct of this project, a rich collection of specimens and data have been
collected. We are in the process of analyzing and reporting this information.
Inquiries for information or collaboration should be directed the Principle
Investigator (Dr Antonino Catanzaro) using the e mail address, gcdd@ucsd.edu.
Authors’ contributions
Conceived and designed the experiments: EJG TGG TCR DGC RG AC. Performed
the experiments: AT CR VC TCV. Analyzed the data: EJG TGG NH AT RLJ DGC.
Contributed reagents/materials/analysis tools: EJG TGG NH AC TCR DGC RLJ AT.
Wrote the paper: EJG TGG NH DGC AC. Provided oversight to GCDD: TGG AC
TCR RG. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was registered with ClinicalTrials.gov (#NCT02170441) and was
reviewed and approved by an academic Human Research Protection Program
and each of the study sites. The primary IRB was approved at University of
California San Diego Human Research Protection Program. Participation did not
include any changes to the standard of care. All study participants or their legal
guardian/representative provided written informed consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Family Medicine and Public Health, University of California
San Diego, 9500 Gilman Dr, #0994, San Diego, CA, USA. 2VA San Diego
Healthcare System, San Diego, CA, USA. 3Department of Biomedical Sciences,
Stellenbosch University, Cape Town, South Africa. 4Department of Medicine,
University of California, San Diego, CA, USA. 5University of Arkansas, Little
Rock, USA. 6Hinduja National Hospital, Mumbai, India. 7Microbiology and
Morphology Laboratory, Institute of Phthisiopneumology, Chisinau, Moldova.
Received: 1 May 2017 Accepted: 30 January 2018
References
1. World Health Organization (WHO): Global tuberculosis report 2013. 2013.
2. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN,
Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al. American Thoracic
Society/Centers for Disease Control and Prevention/Infectious Diseases
Society of America: treatment of tuberculosis. Am J Respir Crit Care Med.
2003;167(4):603–62.
3. Andrews JR, Shah NS, Weissman D, Moll AP, Friedland G, Gandhi NR.
Predictors of multidrug- and extensively drug-resistant tuberculosis in a
high HIV prevalence community. PLoS One. 2010;5(12):e15735.
4. Dharmadhikari AS, Mphahlele M, Venter K, Stoltz A, Mathebula R, Masotla T,
van der Walt M, Pagano M, Jensen P, Nardell E. Rapid impact of effective
treatment on transmission of multidrug-resistant tuberculosis. Int J Tuberc
Lung Dis. 2014;18(9):1019–25.
5. Engstrom A, Morcillo N, Imperiale B, Hoffner SE, Jureen P. Detection of first-
and second-line drug resistance in mycobacterium tuberculosis clinical
isolates by pyrosequencing. J Clin Microbiol. 2012;50(6):2026–33.
6. McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K,
Lawn S, Grobusch MP, Memish Z, et al. Tuberculosis diagnostics and
biomarkers: needs, challenges, recent advances, and opportunities. J Infect
Dis. 2012;205(Suppl 2):S147–58.
7. Toosky M, Javid B. Novel diagnostics and therapeutics for drug-resistant
tuberculosis. Br Med Bull. 2014;110(1):129–40.
8. Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert M,
Georghiou SB, Trollip A, Groessl E, Hillery N, et al. Performance comparison
of three rapid tests for the diagnosis of drug-resistant tuberculosis. PLoS
One. 2015;10(8):e0136861.
9. Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein
RS, Lin SY, Eisenach K, Ganiats TG, et al. The global consortium for drug-
resistant tuberculosis diagnostics (GCDD): design of a multi-site, head-to-
head study of three rapid tests to detect extensively drug-resistant
tuberculosis. Trials. 2014;15(1):434.
10. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT,
Blakemore R, Worodria W, Gray C, et al. Feasibility, diagnostic accuracy, and
effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of
tuberculosis and multidrug resistance: a multicentre implementation study.
Lancet. 2011;377(9776):1495–505.
11. Pang Y, Li Q, Ou X, Sohn H, Zhang Z, Li J, Xia H, Kam KM, O'Brien RJ, Chi J,
et al. Cost-effectiveness comparison of Genechip and conventional drug
susceptibility test for detecting multidrug-resistant tuberculosis in China.
PLoS One. 2013;8(7):e69267.
12. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for
diagnosis of tuberculosis and drug-resistant tuberculosis: a cost and
affordability analysis. Eur Respir J. 2013;42(3):708–20.
13. Dowdy DW, van't Hoog A, Shah M, Cobelens F. Cost-effectiveness of rapid
susceptibility testing against second-line drugs for tuberculosis. Int J Tuberc
Lung Dis. 2014;18(6):647–54.
14. Balabanova Y, Drobniewski F, Nikolayevskyy V, Kruuner A, Malomanova N,
Simak T, Ilyina N, Zakharova S, Lebedeva N, Alexander HL, et al. An
integrated approach to rapid diagnosis of tuberculosis and multidrug
resistance using liquid culture and molecular methods in Russia. PLoS One.
2009;4(9):e7129.
15. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. Drug susceptibility
testing of mycobacterium tuberculosis against second-line drugs using the
Bactec MGIT 960 system. Int J Tuberc Lung Dis. 2008;12(12):1449–55.
16. Almeida D, Rodrigues C, Udwadia ZF, Lalvani A, Gothi GD, Mehta P, Mehta
A. Incidence of multidrug-resistant tuberculosis in urban and rural India and
implications for prevention. Clin Infect Dis. 2003;36(12):e152–4.
Groessl et al. BMC Infectious Diseases  (2018) 18:102 Page 9 of 10
17. Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, Serbulenco A,
Zignol M, Dadu A, Dara M, et al. Assessing spatial heterogeneity of
multidrug-resistant tuberculosis in a high-burden country. Eur Respir J. 2013;
42(5):1291–301.
18. Useful Lives Table. Office of the Controller. Chicago: Northwestern
University; 2013. http://www.northwestern.edu/controller/accounting-
services/equipment-inventory/docs/useful-lives-table.xls. Accessed July 2013.
19. Latimer EA, Becker ER. Incorporating practice costs into the resource-based
relative value scale. Med Care. 1992;30(11 Suppl):NS50–60.
20. Physician Payment Review Commission. Practice expenses under the
Medicare fee schedule: a resource-based approach. Washington, DC:
Physician Payment Review Commission; 1992.
21. Groessl EJ, Kaplan RM, Blair SN, Rejeski WJ, Katula JA, King AC, Fielding RA,
Glynn NW, Pahor M. A cost analysis of a physical activity intervention for
older adults. J Phys Act Health. 2009;6(6):767–74.
22. Herman WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE,
Lachin JM, Engelgau MM. Costs associated with the primary prevention of
type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care.
2003;26(1):36–47.
23. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health
and medicine. New York, NY: Oxford University Press; 1996.
24. Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert
M, Georghiou SB, Trollip A, Groessl EG, Hillery N, et al. Performance
comparison of three rapid tests for the diagnosis of drug-resistant
tuberculosis. PLoS One. in press;
25. Ogwang S, Asiimwe BB, Traore H, Mumbowa F, Okwera A, Eisenach KD,
Kayes S, Jones-Lopez EC, McNerney R, Worodria W, et al. Comparison of
rapid tests for detection of rifampicin-resistant mycobacterium tuberculosis
in Kampala, Uganda. BMC Infect Dis. 2009;9:139.
26. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of
diagnosis and management of drug resistant tuberculosis in South Africa?
PLoS One. 2013;8(1):e54587.
27. Shah M, Chihota V, Coetzee G, Churchyard G, Dorman SE. Comparison of
laboratory costs of rapid molecular tests and conventional diagnostics for
detection of tuberculosis and drug-resistant tuberculosis in South Africa.
BMC Infect Dis. 2013;13:352.
28. Leung E, Minion J, Benedetti A, Pai M, Menzies D. Microcolony culture
techniques for tuberculosis diagnosis: a systematic review. Int J Tuberc Lung
Dis. 2012;16(1):16–23. i-iii
29. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, Sanchez E,
Pinedo Y, Saravia JC, Salazar C, et al. Microscopic-observation drug-
susceptibility assay for the diagnosis of TB. N Engl J Med. 2006;355(15):1539–50.
30. Solari L, Gutierrez A, Suarez C, Jave O, Castillo E, Yale G, Ascencios L, Quispe N,
Valencia E, Suarez V. Cost analysis of rapid methods for diagnosis of multidrug
resistant tuberculosis in different epidemiologic groups in Peru. Revista
peruana de medicina experimental y salud publica. 2011;28(3):426–31.
31. Georghiou SB, Seifert M, Lin SY, Catanzaro D, Garfein RS, Jackson RL, Crudu
V, Rodrigues C, Victor TC, Catanzaro A, et al. Shedding light on the
performance of a pyrosequencing assay for drug-resistant tuberculosis
diagnosis. BMC Infect Dis. 2016;16:458.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Groessl et al. BMC Infectious Diseases  (2018) 18:102 Page 10 of 10
